Incruse Ellipta 55mcg (umeclidinium bromide) for the relief of symptoms in adult patients with Chronic Obstructive Pulmonary Disease (COPD):
|
|
- Britney Sherman
- 5 years ago
- Views:
Transcription
1 Incruse Ellipta 55mcg (umeclidinium bromide) for the relief of symptoms in adult patients with Chronic Obstructive Pulmonary Disease (COPD): An introduction for Clinical Commisioning Groups and Health Boards BRAND NAME GENERIC NAME LICENSED INDICATION THERAPEUTIC CLASS ANTICIPATED PLACE IN THERAPY DOSAGE Incruse Ellipta Umeclidinium bromide Maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD) Incruse Ellipta is a long acting muscarinic receptor antagonist (also referred to as an anticholinergic or LAMA). Where LAMAs are currently positioned within UK guidelines for the treatment of patients with COPD, either as monotherapy or triple therapy with an ICS/LABA Incruse Ellipta 55 micrograms inhalation powder (delivered dose). This corresponds to a pre-dispensed dose of Incruse 62.5 micrograms The recommended dose in adults (also the maximum dose) is one inhalation of Incruse Ellipta once daily at the same time of the day each day. ADMINISTRATION Inhaled via an Ellipta multi-dose dry powder inhaler COST The 30-day cost of Incruse Ellipta is REGULATORY STATUS Marketing Authorisation was received on 28th April 2014 Prescribing Information can be found at the end of this document.
2 Clinical efficacy 1-3 Incruse was evaluated in 904 adult patients who received umeclidinium bromide or placebo from two Phase III clinical studies with a clinical diagnosis of COPD; a 12-week study 2 and a 24-week study. 3 These were both randomised, double-blind, parallel group, placebo-controlled studies. Synopsis of Incruse studies 12-WEEK STUDY 2 24-WEEK STUDY 3 12-week treatment period (84 days) 69 subjects in the umeclidinium 55mcg once-daily treatment arm vs 68 subjects in the placebo arm Primary endpoint: Trough FEV 1 on day 85 Key secondary end-points: Weighted mean (wm) FEV h post-dose on days 1, 28 and 84, and serial FEV 1 at 1, 3, 6, 23 and 24 h post-dose on days 1 and week treatment period (168 days) 418 subjects in the umeclidinium 55mcg once-daily treatment arm vs 280 subjects in the placebo arm Primary Efficacy Endpoint: Trough FEV 1 on Day 169 Key secondary end-points: Weighted mean (wm) FEV h post-dose on days 168 and trough and 0-6 h wm FEV 1 at other visits, serial FEV 1 assessments Results Incruse has demonstrated statistically significant and clinically meaningful improvements in lung function compared with placebo after the first day of treatment which were maintained over the 12-week and 24-week treatment periods. 1 INCRUSE 12-WEEK STUDY 2 INCRUSE 24-WEEK STUDY 3 Trough FEV 1 on Day 85 with Umec 55mcg (n=69) Trough FEV 1 on Day 169 with Umec 55 mcg (n=418) Difference vs placebo (ml) 127 Difference vs placebo (ml) % CI (52,202) 95% CI (76,155) p-value <0.001 p-value <0.001 Figure 1 2 : Change from baseline in trough forced expiratory volume in 1 s (FEV 1 ). Adapted from Trivedi et al., Figure 2 3 : Change from baseline in trough forced expiratory volume in 1 s (FEV 1 ). Adapted from J.F. Donahue et al., Change in trough FEV1 from baseline (ml) Placebo Umec 55mcg LS mean (95% Cl) change from baseline (ml) Placebo Umec 55 mcg Time (days) Time (days) All data are presented as least square means with 95% confidence intervals.
3 Incruse Ellipta demonstrated clinically meaningful improvements 4 in breathlessness (TDI focal score) compared to placebo over 12 weeks (1.0 unit, p=ns) 2 and 24 weeks (1.0 unit, p<0.001) 3, although the improvement seen in the 12 week study was not statistically significant. Incruse also demonstrated an improvement in health-related quality of life measured using the St. George s Respiratory Questionnaire (SGRQ); (12 week study: units, p<0.001; 24 week study: units, p=ns*). 1-3 In the 24 week study, Incruse lowered the risk of a COPD exacerbation compared with placebo (8.9% vs 13.7%; hazard ratio 0.6). 3 * This study was not specifically designed to evaluate the effects of treatments on COPD exacerbations. * A step-down statistical testing procedure was used in this study and this comparison was below a comparison that did not achieve statistical significance. Therefore, statistical significance on this comparison cannot be inferred. Incruse Ellipta in combination with Relvar Ellipta (vilanterol/fluticasone furoate) 92/22 mcg has demonstrated statistically significant and clinically meaningful improvements in lung function compared with placebo in combination with Relvar Ellipta 92/22 mcg 5,6 In two similar Phase III studies, adding Incruse Ellipta to Relvar Ellipta 92/22mcg demonstrated (compared to placebo in combination with Relvar Ellipta 92/22mcg): statistically significant improvements in lung function (trough FEV 1 ) in both studies at week 12 (124mL, p<0.001; 122mL, p<0.001) 5,6 statistically significant reduction in rescue salbutamol use in both studies over 12 weeks (0.4 puffs per day, p<0.001; 0.3 puffs per day, p=0.003) 5,6 improvements in health-related quality of life scores (as measured by SGRQ) at week 12 (-0.82 units, p=ns; units, p=0.011) 5,6, although the reduction seen in one of the studies was not statistically significant Relvar Ellipta is licensed for the symptomatic treatment of adults with COPD with a FEV 1 <70% predicted normal (post-bronchodilator) and an exacerbation history despite regular bronchodilator therapy 11 Safety profile of Incruse Ellipta 1 The safety profile of Incruse was evaluated from 1663 patients with COPD who received doses of 55 micrograms or greater for up to one year. This includes 576 patients who received the recommended dose of 55 micrograms once daily. The most frequently reported adverse reactions with Incruse were nasopharyngitis and upper respiratory tract infection. SYSTEM ORGAN CLASS ADVERSE REACTIONS FREQUENCY Infections and infestations Nasopharyngitis Upper respiratory tract infection Urinary tract infection Sinusitis Pharyngitis Infections and infestations Headache Cardiac disorders Tachycardia Atrial fibrillation Rhythm idioventricular Supraventricular tachycardia Supraventricular extrasystoles Respiratory, thoracic and mediastinal disorders Cough Gastrointestinal disorders Constipation Dry mouth Skin and subcutaneous tissue disorders Rash
4 Safety profile of Relvar Ellipta in COPD In the COPD clinical development programme a total of 6,237 subjects were included in an integrated assessment of adverse reactions. The most commonly reported adverse reactions with fluticasone furoate and vilanterol were headache and nasopharyngitis. 11 With the exception of pneumonia and fractures, the safety profile was similar in patients with asthma and COPD. During clinical studies, pneumonia and fractures were more frequently commonly observed in patients with COPD The risk of pneumonia in COPD with Relvar 92/22 mcg is similar to that reported for other ICS/LABAs within independent Cochrane meta-analysis. 11,12,13 - Pneumonia occurred in 6% of patients on Relvar Ellipta 92/22 mcg compared with 3% of patients receiving vilanterol 22 mcg alone The number of pneumonia events per 1000 patient years was 85.7 with Relvar Ellipta 92/22 mcg and 42.3 with vilanterol 22 mcg. 11 Ellipta inhaler 1 Incruse is delivered in the Ellipta inhaler. Straightforward to use 7 and is preferred vs. HandiHaler with regard to the number of steps to use, time taken to use and overall preference for the inhaler. 8 Patients reported high levels of satisfaction with and a very positive experience of using the Ellipta inhaler. 7 Drivers of patient preference when using the Ellipta inhaler have shown to be: ease of handling; size; portability and storage; the shape of the mouthpiece and seal made with the lips on inhalation; and the size and visibility of the dose counter. 7 Cost LAMA 30-DAY COST 9 LAMA & ICS/LABA 30-DAY COST 9 Incruse Ellipta 55 mcg Seebri Breezhaler (glycopyrronium bromide) 50 mcg Eklira Genuair (aclidinium bromide) 322 mcg Spiriva Handihaler (tiotropium bromide) 18 mcg Spiriva Respimat (tiotropium bromide) 2.5 mcg Incruse Ellipta 55 mcg & Relvar Ellipta (vilanterol/ fluticasone furoate) 92/22 mcg Spiriva * Handihaler 18mcg & Seretide ** Accuhaler 500/50 mcg *most prescribed LAMA 10 **most prescribed ICS/LABA GSK s respiratory portfolio and the role of Incruse GSK have developed a portfolio of respiratory medicines to help meet the needs of patients and healthcare professionals. Incruse Ellipta is an effective 2,3 once-daily LAMA 1 which completes our current COPD portfolio of inhaled medicines. Incruse Ellipta is an option for delivering single bronchodilation for breathless patients needing a LAMA. Combining Incruse with Relvar as part of triple therapy provides patients with the first once-daily triple-therapy combination 1,11, delivered through the same straightforward and patient-preferred Ellipta inhaler 4,5, (one Incruse Ellipta inhaler and one Relvar Ellipta inhaler), with potential cost-savings for the NHS 9.
5 References: 1. Incruse Ellipta Summary of Product Characteristics; accessed January Roopa Trivedi, Nathalie Richard, Rashmi Mehta, Alison Church. Umeclidinium in patients with COPD: a randomised, placebo-controlled study. European Respiratory Journal 2014; 43: J. F. Donohue, M. R. Maleki-Yazdi, S. Kilbride, R. Mehta, C. Kalberg, A. Church. Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPD. Respiratory Medicine 2014; 107: Mahler DA, Witek TJ, Jr. The MCID of the transition dyspnea index is a total score of one unit. COPD 2005; 2(1): Data on file UK/INC/0009/ Data on file UK/INC/0015/ Hendrik Svedsater, Peter Dale, Karl Garrill, Richard Walker, Mark W Woepse. Qualitative assessment of attributes and ease of use of the ELLIPTA dry powder inhaler for delivery of maintenance therapy for asthma and COPD. BMC Pulmonary Medicine 2013; 13(72). 8. J H Riley, M M Tabberer, N Richard, A C Donald, A Church, S S Harris. Use of a new dry powder inhaler to deliver umeclidinium/vilanterol in the treatment of COPD: Annual Congress of the European Respiratory Society (ERS) 2013; poster P emims; LAMA and ICS/LABA prices; accessed January CSD Patient Data, Cegedim Strategic Data Ltd, MAT May Relvar Ellipta 92/22mcg Summary of Product Characteristics; accessed January Kew et al. Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease. Cochrane Database Syst.Rev. 2014; 3:CD Nannini et al. Combined corticosteroid and long-acting beta 2 -agonist in one inhaler versus long-acting beta 2 -agonists for chronic obstructive pulmonary disease. Cochrane Database Syst.Rev.2012; 9:CD Dransfield MT et al. A once-daily inhaled coricosteroid, long-acting beta 2 -agonist combination, fluticasone furoate (FF)/vilanterol (VI), for the prevention of COPD exacerbations. Lancet Resp Med 2013; 1(3): Prescribing information Incruse Ellipta (umeclidinium bromide) (Please consult the full Summary of Product Characteristics (SmPC) before prescribing) Incruse Ellipta 55 (umeclidinium) inhalation powder. Each single inhalation provides a delivered dose (the dose leaving the mouthpiece of the inhaler) of 55 micrograms umeclidinium (equivalent to 65 micrograms of umeclidinium bromide). This corresponds to a pre-dispensed dose of 62.5 micrograms umeclidinium equivalent to 74.2 micrograms umeclidinium bromide. Indications: COPD: Maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD). Dosage and administration: Inhalation only. COPD: One inhalation once daily of Incruse Ellipta at the same time of the day each day. Contraindications: Hypersensitivity to the active substances or to any of the excipients (lactose monohydrate and magnesium stearate). Precautions: Incruse Ellipta should not be used in patients with asthma. Treatment with Incruse Ellipta should be discontinued in the event of paradoxical bronchospasm and alternative therapy initiated if necessary. Cardiovascular effects may be seen after the administration of muscarinic receptor antagonists, therefore Incruse Ellipta should be used with caution in patients with severe cardiovascular disorders, particularly cardiac arrhythmias. Incruse Ellipta should be used with caution in patients with urinary retention or narrow angle glaucoma. No dosage adjustment is required in renal or mild to moderate hepatic impairment. Acute symptoms: Incruse Ellipta is not indicated for acute episodes of bronchospasm. Warn patients to seek medical advice if short-acting inhaled bronchodilator use increases, a re-evaluation of the patient and of the COPD treatment regimen should be undertaken. Interactions with other medicinal products: Coadministration of umeclidinium bromide with other long-acting muscarinic antagonists or medicinal products containing this active substance has not been studied and therefore, is not recommended. Fertility, pregnancy, and breast-feeding: No available human invivo data. Balance risks against benefits. Side effects: : nasopharyngitis, upper respiratory tract infection, headache, urinary tract infection sinusitis, tachycardia and cough. : pharyngitis, atrial fibrillation, rhythm idioventricular, supraventricular tachycardia, supraventricular extrasystoles, rash, dry mouth and constipation. Legal category: POM. Presentation and Basic NHS cost: Incruse Ellipta. 1 inhaler x 30 doses. Incruse Ellipta Marketing authorisation (MA) nos. 55mcg 1x30 doses [EU/1/14/922/002]; MA holder: Glaxo Group Ltd, 980 Great West Road, Brentford, Middlesex TW8 9GS, UK. Last date of revision: December UK/RESP/0122/14(2). Incruse and Ellipta are registered trademarks of the GlaxoSmithKline group of companies. All rights reserved. Adverse events should be reported. Reporting forms and information can be found at Adverse events should also be reported to GlaxoSmithKline on Prescribing information Relvar Ellipta (fluticasone furoate/vilanterol [as trifenatate]) (Please consult the full Summary of Product Characteristics (SmPC) before prescribing) Relvar Ellipta (fluticasone furoate/vilanterol [as trifenatate]) inhalation powder. Each single inhalation of fluticasone furoate (FF) 100 micrograms (mcg) and vilanterol (VI) 25mcg provides a delivered dose of 92mcg FF and 22mcg VI. Each single inhalation of FF 200mcg and VI 25mcg provides a delivered dose of 184mcg of FF and 22mcg of VI. Indications: Asthma: Regular treatment of asthma in patients 12 years and older not adequately controlled on inhaled corticosteroids and as needed short-acting inhaled β 2 -agonists, where a long-acting β 2 -agonist and inhaled corticosteroid combination is appropriate. COPD: Symptomatic treatment of adults with COPD with a FEV 1 <70% predicted normal (post-bronchodilator) and an exacerbation history despite regular bronchodilator therapy. Dosage and administration: Inhalation only. Asthma: Adults and adolescents 12 years: one inhalation once daily of: Relvar 92/22mcg for patients who require a low to mid dose of inhaled corticosteroid in combination with a long-acting β 2 -agonist. If patients are inadequately controlled then the dose can be increased to one inhalation once daily Relvar 184/22mcg. Relvar 184/22mcg can also be considered for patients who require a higher dose of inhaled corticosteroid in combination with a long-acting β 2 -agonist. Regularly review patients and reduce dose to lowest that maintains effective symptom control. COPD: one inhalation once daily of Relvar 92/22mcg. Contraindications: Hypersensitivity to the active substances or to any of the excipients (lactose monohydrate & magnesium stearate). Precautions: Pulmonary tuberculosis, severe cardiovascular disorders, chronic or untreated infections, diabetes mellitus. Paradoxical bronchospasm substitute alternative therapy if necessary. In patients with hepatic with moderate to severe impairment 92/22mcg dose should be used. Acute symptoms: Not for acute symptoms, use short-acting inhaled bronchodilator. Warn patients to seek medical advice if short-acting inhaled bronchodilator use increases. Therapy should not be abruptly stopped without physician supervision due to risk of symptom recurrence. Asthma-related adverse events and exacerbations may occur during treatment. Patients should continue treatment but seek medical advice if asthma symptoms remain uncontrolled or worsen after initiation of Relvar. Systemic effects: Systemic effects of inhaled corticosteroids may occur, particularly at high doses for long periods, but much less likely than with oral corticosteroids. Possible Systemic effects include: Cushing s syndrome, Cushingoid features, adrenal suppression, decrease in bone mineral density, growth retardation in children and adolescents, cataract, glaucoma. More rarely, a range of psychological or behavioural effects including psychomotor hyperactivity, sleep disorders, anxiety, depression or aggression (particularly in children). Increased incidence of pneumonia has been observed in patients with COPD receiving Relvar. Risk factors for pneumonia include: current smokers, patients with a history of prior pneumonia, patients with a body mass index <25 kg/m 2 and patients with a FEV 1 <50% predicted. If pneumonia occurs with Relvar treatment should be re-evaluated. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take Relvar. Interactions with other medicinal products: Interaction studies have only been performed in adults. Avoid β-blockers. Caution is advised when co-administering with strong CYP 3A4 inhibitors (e.g. ketoconazole, ritonavir). Concomitant administration of other sympathomimetic medicinal products may potentiate the adverse reactions of FF/VI. Relvar should not be used in conjunction with other long-acting β 2 -adrenergic agonists or medicinal products containing long-acting β 2 -adrenergic agonists. Pregnancy and breast-feeding: Experience limited. Balance risks against benefits. Side effects: Very ( 1/10): Headache, nasopharyngitis. ( 1/100 to <1/10): Candidiasis of the mouth and throat, dysphonia, pneumonia, bronchitis, upper respiratory tract infection, influenza, oropharyngeal pain, sinusitis, pharyngitis, rhinitis, cough, abdominal pain, arthralgia, back pain, fractures, pyrexia. ( 1/1,000 to <1/100): Extrasystoles. Rare ( 1/10,000 to <1/1,000); Hypersensitivity reactions including anaphylaxis, angioedema, rash, and urticaria. Legal category: POM. Presentation and Basic NHS cost: Relvar Ellipta. 1 inhaler x 30 doses. Relvar Ellipta 92/ Relvar Ellipta 184/ Marketing authorisation (MA) nos. 92/22mcg 1x30 doses [EU/1/13/886/002]; 184/22mcg 1x30 doses [EU/1/13/886/005]. MA holder: Glaxo Group Ltd, 980 Great West Road, Brentford, Middlesex TW8 9GS, UK. Last date of revision: December UK/RESP/0332/14. Relvar and Ellipta are registered trademarks of the GlaxoSmithKline group of companies. All rights reserved. Relvar Ellipta was developed in collaboration with Theravance, Inc. Adverse events should be reported. Reporting forms and information can be found at Adverse events should also be reported to GlaxoSmithKline on Seretide and Accuhaler are registered trademarks of the GlaxoSmithKline group of companies. Seebri and Breezhaler are registered trademarks of Novartis Pharmaceuticals. Eklira and Genuair are registered trademarks of Almirall. Spiriva, Handihaler and Respimat are registered trademarks of Boehringer Ingelheim Pharma. RELVAR ELLIPTA was developed in collaboration with 2014 GSK group of companies. All Rights Reserved.
The only COPD Triple Therapy delivered in a single daily inhalation. 1 Improvement in quality of life vs. ICS/LABA. 2
The only COPD Triple Therapy delivered in a single daily inhalation. 1 Improvement in quality of life vs. ICS/LABA. 2 Trelegy Ellipta is indicated for maintenance treatment in adult patients with moderate-to-severe
More informationInforMing the PAthway of COPD Treatment 1
InforMing the PAthway of COPD Treatment 1 A landmark trial in over 10,000 symptomatic COPD patients who had experienced at least one exacerbation in the last 12 months 1 (fluticasone furoate/umeclidinium/vilanterol)
More informationWhat is the current cost of COPD (Chronic Obstructive Pulmonary Disease) therapies?
What is the current cost of COPD (Chronic Obstructive Pulmonary Disease) therapies? Medicines in the COPD Ellipta portfolio are highlighted in orange on the graph below: Incruse Ellipta (umeclidinium)
More informationBudgetary Implications of Introducing the GSK Ellipta Portfolio for COPD in the UK
Budgetary Implications of Introducing the GSK Ellipta Portfolio for COPD in the UK Poster No. PRS20 Harding T 1, Thompson G 1, Mulley P 2 1 Health Outcomes, UK Pharma, GlaxoSmithKline, Stockley Park, UK
More informationCase Study Simplifying and streamlining COPD treatment
Case Study Simplifying and streamlining COPD treatment The production of this case study has been organised and sponsored by GlaxoSmithKline. The healthcare professional involved received no payment for
More informationRelvar Ellipta (fluticasone furoate and vilanterol as trifenatate) for the treatment of patients with COPD
Relvar Ellipta (fluticasone furoate and vilanterol as trifenatate) for the treatment of patients with COPD Medicines evidence pack to support formulary and guidelines decision making Prescribing information
More informationumeclidinium, 55 micrograms, powder for inhalation (Incruse ) SMC No. (1004/14) GlaxoSmithKline
umeclidinium, 55 micrograms, powder for inhalation (Incruse ) SMC No. (1004/14) GlaxoSmithKline 07 November 2014 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product
More informationAnoro Ellipta 55/22mcg (umeclidinium and vilanterol) for the Treatment of Chronic Obstructive Pulmonary Disease (COPD)
Anoro Ellipta 55/22mcg (umeclidinium and vilanterol) for the Treatment of Chronic Obstructive Pulmonary Disease (COPD) Medicines Evidence Pack to Support Formulary and Guidelines Decision Making Prescribing
More informationA comparison of once-daily triple therapy with once-daily dual therapy in the treatment of symptomatic COPD
A comparison of once-daily triple therapy with once-daily dual therapy in the treatment of symptomatic COPD The IMPACT trial EVIDENCE UPDATE This Guidelines supplement has been commissioned by GlaxoSmithKline.
More informationumeclidinium/vilanterol, 55/22 micrograms, inhalation powder (Anoro ) SMC No. (978/14) GlaxoSmithKline
umeclidinium/vilanterol, 55/22 micrograms, inhalation powder (Anoro ) SMC No. (978/14) GlaxoSmithKline 04 July 2014 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product
More informationThis supplement has been developed in partnership with GlaxoSmithKline. Evidence Update
This supplement has been developed in partnership with GlaxoSmithKline cpd credits Evidence Update Respiratory A comparison of once-daily triple therapy with once-daily dual therapy in the treatment of
More informationEvidence Summary to support COPD formulary decision making and guideline development
Evidence Summary to support COPD formulary decision making and guideline development Prescribing and adverse event reporting information can be found on the final page of this document. Trelegy and Ellipta
More informationEvidence Summary to support COPD formulary decision making and guideline development
Evidence Summary to support COPD formulary decision making and guideline development Prescribing and adverse event reporting information can be found on the final pages of this document. Anoro, and Ellipta
More informationThe study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationaclidinium 322 micrograms inhalation powder (Eklira Genuair ) SMC No. (810/12) Almirall S.A.
aclidinium 322 micrograms inhalation powder (Eklira Genuair ) SMC No. (810/12) Almirall S.A. 05 October 2012 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and
More informationglycopyrronium 44 micrograms hard capsules of inhalation powder (Seebri Breezhaler ) SMC No. (829/12) Novartis Pharmaceuticals Ltd.
glycopyrronium 44 micrograms hard capsules of inhalation powder (Seebri Breezhaler ) SMC No. (829/12) Novartis Pharmaceuticals Ltd. 07 December 2012 The Scottish Medicines Consortium (SMC) has completed
More informationINCRUSE ELLIPTA PRODUCT INFORMATION
INCRUSE ELLIPTA PRODUCT INFORMATION NAME OF THE MEDICINE Umeclidinium (as bromide) Structure of umeclidinium bromide: OH N O Br Chemical Name: The chemical name of umeclidinium bromide is 1- Azoniabicyclo[2.2.2]octane,
More informationAdjunct Associate Professor Robert Young
Adjunct Associate Professor Robert Young General Physician Auckland City Hospital 7:00-7:55 GlaxoSmithKline Breakfast Session - COPD New approaches in the management of COPD Dr Robert Young BMedSc MBChB
More informationCore Safety Profile. Pharmaceutical form(s)/strength: Dry Powder Inhaler, Nebuliser Suspension, pressurised Metered Dose Inhaler (pmdi)
Core Safety Profile Active substance: Budesonide Pharmaceutical form(s)/strength: Dry Powder Inhaler, Nebuliser Suspension, pressurised Metered Dose Inhaler (pmdi) P - RMS: DK/H/PSUR/0041/001 Date of FAR:
More informationPART VI: SUMMARY OF THE RISK MANAGEMENT PLAN
PART VI: SUMMARY OF THE RISK MANAGEMENT PLAN VI.1 Summary of risk management plan for RELVAR ELLIPTA (fluticasone furoate/vilanterol) This is a summary of the risk management plan (RMP) for RELVAR ELLIPTA.
More informationAWMSG SECRETARIAT ASSESSMENT REPORT. Glycopyrronium bromide (Seebri Breezhaler ) 44 micrograms inhalation powder as hard capsules
AWMSG SECRETARIAT ASSESSMENT REPORT Glycopyrronium bromide (Seebri Breezhaler ) 44 micrograms inhalation powder as hard capsules Reference number: 1455 FULL SUBMISSION This report has been prepared by
More informationRELVAR TM ELLIPTA TM QUALITATIVE AND QUANTITATIVE COMPOSITION
RELVAR TM ELLIPTA TM Fluticasone furoate/vilanterol QUALITATIVE AND QUANTITATIVE COMPOSITION Each single inhalation of fluticasone furoate/vilanterol provides a delivered dose of 92/22 micrograms of fluticasone
More informationMedicines Management of Chronic Obstructive Pulmonary Disease (COPD)
Medicines Management of Chronic Obstructive Pulmonary Disease (COPD) (Chronic & Acute) Guidelines for Primary Care Guideline Authors: Shaneez Dhanji (Wandsworth CCG) Samantha Prigmore (St George s Hospital)
More informationAUSTRALIAN PRODUCT INFORMATION. BREO ELLIPTA (fluticasone furoate/vilanterol trifenatate) powder for inhalation
AUSTRALIAN PRODUCT INFORMATION BREO ELLIPTA (fluticasone furoate/vilanterol trifenatate) powder for inhalation 1 NAME OF THE MEDICINE Fluticasone furoate/vilanterol trifenatate 2 QUALITATIVE AND QUANTITATIVE
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked
More informationFor the use only of Registered Medical Practitioners or a Hospital or a Laboratory. RELVAR ELLIPTA 100 mcg/25 mcg
For the use only of Registered Medical Practitioners or a Hospital or a Laboratory RELVAR ELLIPTA 100 mcg/25 mcg Fluticasone Furoate and Vilanterol Powder for Inhalation QUALITATIVE AND QUANTITATIVE COMPOSITION
More informationRelvar Ellipta (fluticasone furoate/vilanterol [as trifenatate]) for the treatment of patients with asthma
Relvar Ellipta (fluticasone furoate/vilanterol [as trifenatate]) for the treatment of patients with asthma Evidence Summary to support formulary decision making and guideline development Prescribing and
More informationAWMSG SECRETARIAT ASSESSMENT REPORT. Aclidinium bromide (Eklira Genuair ) 322 micrograms inhalation powder. Reference number: 938 FULL SUBMISSION
AWMSG SECRETARIAT ASSESSMENT REPORT Aclidinium bromide (Eklira Genuair ) 322 micrograms inhalation powder Reference number: 938 FULL SUBMISSION This report has been prepared by the All Wales Therapeutics
More informationNHS Dumfries & Galloway Triple therapy in COPD patients over 16 years
Title of Project: NHS Dumfries & Galloway Triple therapy in COPD patients over 16 years 1 Reason for the review Respiratory prescribing is long term and can be costly. Appropriate choice and use of inhaled
More informationNEW ZEALAND DATA SHEET SERETIDE Accuhaler
NEW ZEALAND DATA SHEET SERETIDE Accuhaler Salmeterol xinafoate 50 mcg and Fluticasone (100 mcg, 250 mcg or 500 mcg) Presentation SERETIDE Accuhaler 50 mcg/100 mcg Moulded plastic device containing a foil
More informationNot available 100/6mcg 2 BD formoterol (Fostair MDI) 100/6mcg 33
COMMISSIONING POLICY RECOMMENDATION TREATMENT ADVISORY GROUP FLUTICASONE FUROATE/VILANTEROL COMBINATION INHALER - ASTHMA Policy agreed by Vale of York CCG (date) Drug, Treatment, Device name Fluticasone
More informationCHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) TREATMENT GUIDELINES
CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) TREATMENT GUIDELINES Document Description Document Type Service Application Version Guidelines All healthcare professionals(hcps) caring for patients with asthma
More informationUMEC/VI vs. UMEC in subjects who responded to UMEC UMEC/VI vs. VI in subjects who responded to VI
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationSummary of the risk management plan (RMP) for Laventair (umeclidinium bromide and vilanterol)
EMA/258177/2014 Summary of the risk management plan (RMP) for Laventair (umeclidinium bromide and vilanterol) This is a summary of the risk management plan (RMP) for Laventair, which details the measures
More informationWirral COPD Prescribing Guidelines
Wirral COPD Prescribing Guidelines (To be read in conjunction with the Wirral COPD Supplementary Information) STEP 1: Assess symptoms COPD Assessment Test (CAT) [Link for CAT-test Online] is a patient-completed
More informationDr Stephen Child. Chief Medical Officer Southern Cross Health Society Auckland
Dr Stephen Child Chief Medical Officer Southern Cross Health Society Auckland 7:00-7:55 GlaxoSmithKline Breakfast Session - Hot Topics in Airways Disease: COPD and Asthma Hot Topics in Airways Disease:
More informationCOPD Respiratory Antimuscarinics Drug Class Monograph
Line of Business: Medi-Cal Effective Date: May 17, 2017 Revision Date: May 17, 2017 COPD Respiratory Antimuscarinics Drug Class Monograph This policy has been developed through review of medical literature,
More informationInitial U.S. Approval: 2013
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use BREO ELLIPTA safely and effectively. See full prescribing information for BREO ELLIPTA. BREO ELLIPTA
More informationA COPD medication delivery device option: an overview of the NEOHALER
A COPD medication delivery device option: an overview of the NEOHALER 2017 Sunovion Pharmaceuticals Inc. All rights reserved 9/17 RESP019-17 Indication and Boxed Warning INDICATION ARCAPTA NEOHALER (indacaterol)
More informationfluticasone furoate / vilanterol 92/22, 184/22 micrograms inhalation powder (Relvar Ellipta ) SMC No. (966/14) GlaxoSmithKline UK
fluticasone furoate / vilanterol 92/22, 184/22 micrograms inhalation powder (Relvar Ellipta ) SMC No. (966/14) GlaxoSmithKline UK 09 May 2014 The Scottish Medicines Consortium (SMC) has completed its assessment
More informationEvidence Review for Prescribing Clinical Network
Summary page Evidence Review for Prescribing Clinical Network Treatment: LABA/LAMA Combination devices in COPD Anoro Ellipta, Ultibro and Duaklir Genuair Prepared by: Noreen Devanney Topic Submitted by:
More informationChronic obstructive pulmonary disease
nice bulletin Chronic obstructive pulmonary disease NICE provided the content for this booklet which is independent of any company or product advertised nice bulletin Chronic obstructive pulmonary disease
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Co-Primary Outcomes/Efficacy Variables:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationUtibron Neohaler. (indacaterol, glycopyrrolate) New Product Slideshow
Utibron Neohaler (indacaterol, glycopyrrolate) New Product Slideshow Introduction Brand name: Utibron Neohaler Generic name: Indacaterol, glycopyrrolate Pharmacological class: Long-acting beta2- agonist
More informationAlgorithm for the use of inhaled therapies in COPD
Berkshire West Integrated Care System Representing Berkshire West Clinical Commisioning Group Royal Berkshire NHS Foundation Trust Berkshire Healthcare NHS Foundation Trust Berkshire West Primary Care
More informationSee 17 for PATIENT COUNSELING INFORMATION and FDAapproved. Revised: 12/2017
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use BREO ELLIPTA safely and effectively. See full prescribing information for BREO ELLIPTA. BREO ELLIPTA
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Relvar Ellipta 92 micrograms/22 micrograms inhalation powder, pre-dispensed 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each
More informationNEW ZEALAND DATA SHEET SEREVENT Accuhaler
NEW ZEALAND DATA SHEET SEREVENT Accuhaler Salmeterol xinafoate (50 mcg per inhalation) Presentation SEREVENT Accuhaler is a moulded plastic device containing a foil strip with 60 regularly placed blisters
More informationFULL PRESCRIBING INFORMATION
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use INCRUSE ELLIPTA safely and effectively. See full prescribing information for INCRUSE ELLIPTA. INCRUSE
More informationIPRAVENT Rotacaps (Ipratropium bromide)
Published on: 10 Jul 2014 IPRAVENT Rotacaps (Ipratropium bromide) Composition IPRAVENT Rotacaps Each capsule contains: Ipratropium Bromide BP, equivalent to Ipratropium Bromide (anhydrous) 40 mcg Excipient..q.s.
More informationSurveillance report Published: 6 April 2016 nice.org.uk. NICE All rights reserved.
Surveillance report 2016 Chronic obstructive pulmonary disease in over 16s: diagnosis and management (2010) NICE guideline CG101 Surveillance report Published: 6 April 2016 nice.org.uk NICE 2016. All rights
More informationPrescribing guidelines: Management of COPD in Primary Care
Prescribing guidelines: Management of COPD in Primary Care Establish diagnosis of COPD in patients 35 years with appropriate symptoms with history, examination and spirometry (FEV1/FVC ratio < 70%) Establish
More information7.2 Part VI.2 Elements for a Public Summary
7.2 Part VI.2 Elements for a Public Summary 7.2.1 Part VI.2.1 Overview of disease epidemiology Chronic obstructive pulmonary disease (COPD) is characterized by persistent airflow limitation that is usually
More informationPRODUCT MONOGRAPH. umeclidinium (as bromide) dry powder for oral inhalation mcg umeclidinium per oral inhalation. Inhaled Bronchodilator
PRODUCT MONOGRAPH Pr INCRUSE ELLIPTA umeclidinium (as bromide) dry powder for oral inhalation 62.5 mcg umeclidinium per oral inhalation Inhaled Bronchodilator Long-Acting Muscarinic Antagonist (LAMA) GlaxoSmithKline
More informationCDEC FINAL RECOMMENDATION
CDEC FINAL RECOMMENDATION (FLUTICASONE FUROATE/VILANTEROL) (Breo Ellipta GlaxoSmithKline) Indication: Chronic Obstructive Pulmonary Disease Recommendation: The Canadian Drug Expert Committee (CDEC) recommends
More informationBEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE
BEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE September 2015 Review Date: September 2018 Bulletin 219: Choice of Long Acting Muscarinic Agent (LAMA) inhaler for COPD JPC Recommendation: The availability
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 15 December 2010
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 15 December 2010 HIROBRIZ BREEZHALER 150 micrograms, inhalation powder, hard capsules B/10 with inhaler (CIP code:
More informationAlgorithm for the use of inhaled therapies in COPD Version 2 May 2017
Algorithm for the use of inhaled therapies in COPD This document has been revised by the Berkshire West Respiratory Network to support clinicians in selecting the most appropriate, cost effective treatments
More informationERS Investor & Analyst Event. Munich Tuesday 9 th September 2014
ERS Investor & Analyst Event Munich Tuesday 9 th September 2014 Darrell Baker SVP, Global Head of Respiratory Agenda GSK s Respiratory Portfolio Eosinophils Research in COPD Eosinophils Clinical Experience
More information14 41 minutes Vd 218 t ½ 22 to 70 Clearance hours Protein Binding 71%, active metabolite 42% Bioavailability 3%
Brand Name: Yupelri Generic Name: revefenacin Manufacturer: Mylan Drug Class: Anticholinergic Uses: Labeled Uses: inhalation solution for maintenance treatment of COPD 1 Unlabeled Uses: no off-label indications
More informationAddress Comorbidities
Greater Manchester COPD Management Plan Non-pharmacological management for ALL patients Smoking Cessation Annual Flu Vaccination Pulmonary Rehabilitation Increase daily activity Inhaler Technique Measure
More informationSummary of the risk management plan (RMP) for Duaklir Genuair (aclidinium / formoterol fumarate dihydrate)
EMA/605453/2014 Summary of the risk management plan (RMP) for Duaklir Genuair (aclidinium / formoterol fumarate dihydrate) This is a summary of the risk management plan (RMP) for Duaklir Genuair, which
More informationApril 10 th, Bond Street, Toronto ON, M5B 1W8
Comprehensive Research Plan: Inhaled long-acting muscarinic antagonists (LAMAs; long-acting anticholinergics) for the treatment of chronic obstructive pulmonary disease (COPD) April 10 th, 2014 30 Bond
More informationRevefenacin (TD-4208) Phase 3 Efficacy Results
Revefenacin (TD-4208) Phase 3 Efficacy Results Once-daily, Nebulized Long-Acting Muscarinic Antagonist (LAMA) October 20, 2016 THERAVANCE, the Cross/Star logo and MEDICINES THAT MAKE A DIFFERENCE are registered
More informationMedical Directive. Activation Date: April 24, 2013 Review due by: December 1, Medical Director: Date: December 1, 2017
Medical Directive Pre and Post Bronchodilator Spirometry Testing and Treatment Initiation Assigned Number: Activation Date: April 24, 2013 Review due by: December 1, 2019 23 Approval Signature & Date Medical
More informationChanging Landscapes in COPD New Zealand Respiratory Conference
Changing Landscapes in COPD New Zealand Respiratory Conference Dr Robert Young BMedSc MBChB DPhil (Oxon) FRACP FRCP Associate Professor Consultant Physician Changing Landscapes in COPD: Summary 1. Overview
More informationOpinion 17 April EKLIRA GENUAIR 322 MICROGRAMS, inhalation powder B/1 inhaler with 60 doses (CIP: )
The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 17 April 2013 EKLIRA GENUAIR 322 MICROGRAMS, inhalation powder B/1 inhaler with 60 doses (CIP: 34009 266 608 0 2)
More informationNew Medicines Committee Briefing July Glycopyrronium bromide/indacaterol (Ultibro ) for maintenance treatment of adults with stable COPD
Ultibro is to be reviewed for use within: New Medicines Committee Briefing July 2017 Glycopyrronium bromide/indacaterol (Ultibro ) for maintenance treatment of adults with stable COPD Summary: Primary
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked
More informationPRODUCT MONOGRAPH. fluticasone furoate/vilanterol (as trifenatate) dry powder for oral inhalation 100 mcg/25 mcg 200 mcg/25 mcg
PRODUCT MONOGRAPH PrBREO ELLIPTA fluticasone furoate/vilanterol (as trifenatate) dry powder for oral inhalation 100 mcg/25 mcg 200 mcg/25 mcg Inhaled Corticosteroid (ICS) and Bronchodilator (Long-Acting
More informationPRODUCT MONOGRAPH ANORO ELLIPTA. umeclidinium (as bromide) and vilanterol (as trifenatate) dry powder for oral inhalation
PRODUCT MONOGRAPH Pr ANORO ELLIPTA umeclidinium (as bromide) and vilanterol (as trifenatate) dry powder for oral inhalation 62.5 mcg umeclidinium and 25 mcg vilanterol per oral inhalation Inhaled Bronchodilator
More informationBEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE
BEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE Bulletin 218: September 2015 Review Date: September 2018 LAMA / LABA combination inhalers in COPD- Place in therapy review and choice of therapy JPC Recommendations:
More informationCHRONIC OBSTRUCTIVE PULMONARY DISEASE
CHRONIC OBSTRUCTIVE PULMONARY DISEASE INCIDENCE UP TO 380,000 PEOPLE IN IRELAND HSE FIGURES 110,000 DIAGNOSED AND 200,000 UNDIAGNOSED. AFFECTS MORE MEN THAN WOMEN BUT RATES ARE RISING 1500 DEATHS PER YEAR
More informationPRODUCT MONOGRAPH. Tiotropium (as tiotropium bromide monohydrate) Inhalation Solution. 2.5 mcg per actuation
PRODUCT MONOGRAPH Pr SPIRIVA RESPIMAT Tiotropium (as tiotropium bromide monohydrate) Inhalation Solution 2.5 mcg per actuation Bronchodilator Long-Acting Muscarinic Antagonist (LAMA) SPIRIVA RESPIMAT cartridge
More informationA randomised, open-label study of umeclidinium versus glycopyrronium in patients with COPD
ORIGINAL ARTICLE COPD A randomised, open-label study of umeclidinium versus glycopyrronium in patients with COPD Tara Rheault 1, Sanjeev Khindri 2, Mitra Vahdati-Bolouri 2, Alison Church 1 and William
More informationSERETIDE EVOHALER. Salmeterol/fluticasone propionate
Abbreviated Prescribing Information based on the International Prescribing Information and prepared to meet the requirements of the GSK International Pharmaceutical Promotional and Marketing Policy. SERETIDE
More informationWhite powder in a light grey inhaler with a pale blue mouthpiece cover and a dose counter.
1. NAME OF THE MEDICINAL PRODUCT Relvar Ellipta 200/25 micrograms inhalation powder, pre-dispensed 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each single inhalation provides a delivered dose (the dose
More informationCo. Durham & Darlington Respiratory Network COPD Treatment Guide
Co. Durham & Darlington Respiratory Network COPD Treatment Guide Age > 35, Productive cough, Breathless, Smoking Hx Spirometry (post-bronchodilator) COPD Advice Intensive smoking cessation support Vaccination
More informationSee 17 for PATIENT COUNSELING INFORMATION and FDAapproved. Revised: 11/2016
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ARNUITY ELLIPTA safely and effectively. See full prescribing information for ARNUITY ELLIPTA. ARNUITY
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked
More informationTHEOPHYLLINE WITH INHALED CORTICOSTEROIDS (TWICS) TRIAL SELF MANAGMENT / ACTION PLANS GENUAIR INHALERS: POTENTIAL SAFETY ISSUE
I S S U E 4 M A R C H / A R P I L 2 0 1 6 Endorsed December 2014 I N S I D E T H I S I S S U E : Theophylline with Inhaled Corticosteroids (TWICS) Trial Genuair Inhaler: Potential Safety Issue 1 Self Management
More informationCOPD: Treatment Update Property of Presenter. Not for Reproduction. Barry Make, MD Professor of Medicine National Jewish Health
COPD: Treatment Update Barry Make, MD Professor of Medicine National Jewish Health Disclosures Advisory board, consultant, multi-center trial, research funding, Data Safety Monitoring Board (DSMB), or
More informationMedicines Optimisation Prescribing Audit: Long acting muscarinic antagonist (LAMA ) review
Medicines Optimisation Prescribing Audit: Long acting muscarinic antagonist (LAMA ) review Aim To identify all patients prescribed long acting muscarinic antagonists (LAMAs) and where clinically appropriate
More informationBEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE
BEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE December 2014 Review date: December 2017 Bulletin 208 : Indacaterol + Glycopyrronium bromide 85/43 micrograms (Ultibro Breezhaler ) for the Treatment
More informationSPIRIVA RESPIMAT (tiotropium bromide) inhalation spray, for oral inhalation Initial U.S. Approval: 2004
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use SPIRIVA RESPIMAT safely and effectively. See full prescribing information for SPIRIVA RESPIMAT. SPIRIVA
More informationCommon Drug Review Pharmacoeconomic Review Report
Common Drug Review Pharmacoeconomic Review Report January 2018 Drug umeclidinium bromide (Incruse Ellipta) Indication Listing request Dosage form(s) Manufacturer Indicated for long-term, once daily maintenance
More informationGMMMG COPD Formulary Inhaler Options October 2017
BNF 3.1.1 Adrenocepter agonists (SABA) Salbutamol Salbutamol Terbutaline Brand name Airsalb Ventolin Evohaler Bricanyl Turbohaler Device MDI MDI Dry powder Strengths 100 microgram 100 microgram 500 microgram
More informationTHE COPD PRESCRIBING TOOL
THE COPD PRESCRIBING TOOL Revised edition, 2017 www.bpac.org.nz/copd CLASSIFICATION The COPD prescribing tool This tool provides pharmacological treatment options for patients with COPD based on their
More informationAUSTRALIAN PRODUCT INFORMATION BRETARIS GENUAIR (ACLIDINIUM BROMIDE)
AUSTRALIAN PRODUCT INFORMATION BRETARIS GENUAIR (ACLIDINIUM BROMIDE) 1. NAME OF THE MEDICINE aclidinium bromide 2. QUALITATIVE AND QUANTITATIVE COMPOSITION BRETARIS GENUAIR 322 micrograms inhalation powder
More informationNew Medicine Recommendation Trimbow
New Medicine Recommendation Trimbow Beclometasone / formoterol / glycopyrronium bromide pressurised metered dose inhaler for treatment of COPD Recommendation: GREEN (restricted) Restriction: Triple therapy
More informationClinical Policy: Roflumilast (Daliresp) Reference Number: CP.PMN.46 Effective Date: Last Review Date: 08.18
Clinical Policy: (Daliresp) Reference Number: CP.PMN.46 Effective Date: 11.01.11 Last Review Date: 08.18 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important
More information